ru
Feedback

Не попадитесь на канал ботавода! Telemetrio находит и помечает такие каналы 👉 Хотите видеть метку — оформите подписку

JAMA (Journal of the American Medical Association)

JAMA (Journal of the American Medical Association)

Открыть в Telegram

All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot

Больше

📈 Аналитический обзор Telegram-канала JAMA (Journal of the American Medical Association)

Канал JAMA (Journal of the American Medical Association) (@jamaupdates) языкового сегмента Английский является активным участником. Сейчас сообщество объединяет 17 092 подписчиков, занимая 1 453 место в категории Медицина и 2 168 место в регионе США.

📊 Показатели аудитории и динамика

С момента создания невідомо проект демонстрирует стремительный рост, собрав аудиторию из 17 092 подписчиков.

Согласно последним данным от 18 ноября, 2026, канал показывает стабильную активность. За последние 30 дней изменение числа участников составило 378, а за последние 24 часа — 18, при этом общий охват остаётся высоким.

  • Статус верификации: Не верифицирован
  • Уровень вовлечённости (ER): Средний показатель вовлечённости аудитории составляет 4.11%. В первые 24 часа после публикации контент обычно набирает 1.80% реакций от общего числа подписчиков.
  • Охват публикаций: В среднем каждый пост получает 702 просмотров. В течение первых суток публикация набирает 307 просмотров.
  • Реакции и взаимодействия: Аудитория активно поддерживает контент: среднее количество реакций на один пост — 1.
  • Тематические интересы: Контент сосредоточен на ключевых темах, таких как patient, disease, treatment, drug, guideline.

📝 Описание и контентная политика

Автор описывает ресурс как площадку для выражения субъективного мнения:
“All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot”

Благодаря высокой частоте обновлений (последние данные получены 19 ноября, 2026) канал поддерживает актуальность и высокий уровень охвата публикаций. Аналитика показывает, что аудитория активно взаимодействует с контентом, что делает его важной точкой влияния в категории Медицина.

17 092
Подписчики
+1824 часа
+807 дней
+37830 дней

Загружаем данные

Привлечение подписчиков
нояб. '26
ноябрь '26
+306
в 1 каналах
октябрь '26
+291
в 0 каналах
Get PRO
сентябрь '26
+301
в 0 каналах
Get PRO
август '26
+361
в 0 каналах
Get PRO
июль '26
+440
в 0 каналах
Get PRO
июнь '26
+422
в 1 каналах
Get PRO
май '26
+584
в 0 каналах
Get PRO
апрель '26
+437
в 0 каналах
Get PRO
март '26
+217
в 0 каналах
Get PRO
февраль '26
+247
в 0 каналах
Get PRO
январь '26
+321
в 0 каналах
Get PRO
декабрь '25
+277
в 0 каналах
Get PRO
ноябрь '25
+366
в 2 каналах
Get PRO
октябрь '25
+164
в 0 каналах
Get PRO
сентябрь '25
+12
в 0 каналах
Get PRO
август '25
+29
в 0 каналах
Get PRO
июль '25
+30
в 0 каналах
Get PRO
июнь '25
+17
в 0 каналах
Get PRO
май '25
+9
в 0 каналах
Get PRO
апрель '25
+5
в 0 каналах
Get PRO
март '25
+17
в 0 каналах
Get PRO
февраль '25
+12
в 0 каналах
Get PRO
январь '25
+18
в 1 каналах
Get PRO
декабрь '24
+237
в 0 каналах
Get PRO
ноябрь '24
+1 122
в 0 каналах
Get PRO
октябрь '24
+1 120
в 0 каналах
Get PRO
сентябрь '24
+1 527
в 1 каналах
Get PRO
август '24
+1 128
в 1 каналах
Get PRO
июль '24
+1 216
в 0 каналах
Get PRO
июнь '24
+781
в 1 каналах
Get PRO
май '24
+797
в 1 каналах
Get PRO
апрель '24
+808
в 1 каналах
Get PRO
март '24
+821
в 2 каналах
Get PRO
февраль '24
+753
в 1 каналах
Get PRO
январь '24
+768
в 0 каналах
Get PRO
декабрь '23
+716
в 1 каналах
Get PRO
ноябрь '23
+96
в 1 каналах
Get PRO
октябрь '23
+86
в 0 каналах
Get PRO
сентябрь '23
+73
в 0 каналах
Get PRO
август '23
+90
в 0 каналах
Get PRO
июль '23
+107
в 0 каналах
Get PRO
июнь '23
+105
в 0 каналах
Get PRO
май '23
+169
в 0 каналах
Get PRO
апрель '23
+128
в 0 каналах
Get PRO
март '23
+84
в 0 каналах
Get PRO
февраль '23
+75
в 0 каналах
Get PRO
январь '23
+71
в 0 каналах
Get PRO
декабрь '22
+74
в 0 каналах
Get PRO
ноябрь '22
+149
в 0 каналах
Get PRO
октябрь '22
+90
в 0 каналах
Get PRO
сентябрь '22
+138
в 0 каналах
Get PRO
август '22
+77
в 0 каналах
Get PRO
июль '22
+50
в 0 каналах
Get PRO
июнь '22
+96
в 0 каналах
Get PRO
май '22
+75
в 0 каналах
Get PRO
апрель '22
+80
в 0 каналах
Get PRO
март '22
+65
в 0 каналах
Get PRO
февраль '22
+26
в 0 каналах
Get PRO
январь '22
+56
в 0 каналах
Get PRO
декабрь '21
+44
в 0 каналах
Get PRO
ноябрь '21
+39
в 0 каналах
Get PRO
октябрь '21
+61
в 0 каналах
Get PRO
сентябрь '21
+66
в 0 каналах
Get PRO
август '21
+65
в 0 каналах
Get PRO
июль '21
+96
в 0 каналах
Get PRO
июнь '21
+120
в 0 каналах
Get PRO
май '21
+130
в 0 каналах
Get PRO
апрель '21
+812
в 0 каналах
Дата
Привлечение подписчиков
Упоминания
Каналы
19 ноября+2
18 ноября+18
17 ноября+4
16 ноября+14
15 ноября+19
14 ноября+10
13 ноября+15
12 ноября+5
11 ноября+17
10 ноября+21
09 ноября+4
08 ноября+12
07 ноября+23
06 ноября+2
05 ноября+17
04 ноября+17
03 ноября+22
02 ноября+76
01 ноября+8
Посты канала
Global Burden of Disease Assessment of Elevated LDL-C https://jamanetwork.com/journals/jama/fullarticle/2857043 To the Editor The Global Burden of Disease 2023 LDL Cholesterol Collaborators provided a timely assessment of the worldwide cardiovascular burden attributable to elevated low-density lipoprotein cholesterol (LDL-C). The finding that this burden is shifting toward middle sociodemographic index (SDI) settings is especially relevant for prevention. We would welcome clarification of 1 analytical choice.
19 нояб., 14:43

2
Trends in Menopause Hormone Therapy https://jamanetwork.com/journals/jama/fullarticle/2857044 This cross-sectional study uses national pharmacy dispensing data to examine menopause hormone therapy dispensing in the US, including by age group as well as formulation and route.
58
3
Some Anniversaries of 1926 https://jamanetwork.com/journals/jama/fullarticle/2857045 From a nationalistic standpoint, the year 1926 has afforded opportunity for notable anniversary celebrations. In this country the sesquicentennial of the declaration of the independence of the United States has assumed the greatest prominence. The history of medicine also affords occasion for retrospect and commemoration. In 1776, the year brought so conspicuously into the public mind at the present time, the Prussian army surgeon Jasser successfully operated on the mastoid; Cruikshank of Edinburgh investigated the reunion and regeneration of severed nerves, and showed that they will grow together again, and Scheele isolated uric acid from the urine.
64
4
Pediatric Medical Imaging and Brain Tumor Risk https://jamanetwork.com/journals/jama/fullarticle/2857046 Computed tomography (CT) and other imaging modalities that use ionizing radiation are central to pediatric care, allowing rapid evaluation of congenital abnormalities, head trauma, acute neurologic deficits, and serious illness. Children require particular attention in radiation protection because their developing tissues are more radiosensitive and their longer life expectancy allows more time for radiation-related cancer to emerge.
62
5
Anemia and Iron Status in Pregnant and Postpartum Women With Acute Heart Failure https://jamanetwork.com/journals/jamacardiology/fullarticle/2856895 This case-control study investigates associations of maternal anemia and iron status with acute heart failure in Indian women during pregnancy and post partum.
349
6
Effect of Acoramidis on Heart Failure-Related Health Status—Reply https://jamanetwork.com/journals/jamacardiology/fullarticle/2856896 In Reply We thank Faiz and Khan for their thoughtful comments on our analysis of health status in ATTRibute-CM. We agree with the central premise of both letters: integrating patient-reported health status with survival in a progressive, fatal disease is methodologically challenging. Death cannot be treated as simply a missing Kansas City Cardiomyopathy Questionnaire (KCCQ) observation, especially when most patients die of cardiovascular causes. There are no ideal statistical methods that account for data missing not at random. Accordingly, any longitudinal analyses incorporating missing data will have strengths and weaknesses, and require making different, unverifiable assumptions.
349
7
Effect of Acoramidis on Heart Failure–Related Health Status https://jamanetwork.com/journals/jamacardiology/fullarticle/2856897 To the Editor The secondary analysis by Sherrod and colleagues of the ATTRibute-CM randomized clinical trial demonstrated that acoramidis produced a statistically significant and clinically meaningful attenuation of decline in health status, as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS), among patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The integration of survival and patient-reported outcomes into composite alive and well, alive and not worse, and alive and better categories represents a valuable contribution to the field, and I commend the authors for this comprehensive, patient-centered analysis. I wish to raise several methodological considerations that we believe merit clarification and that may help readers more accurately gauge the magnitude and generalizability of the reported benefit.
306
8
Effect of Acoramidis on Heart Failure–Related Health Status https://jamanetwork.com/journals/jamacardiology/fullarticle/2856898 To the Editor The study by Sherrod et al reported that acoramidis significantly slows down the decline in Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS) vs placebo in transthyretin amyloid cardiomyopathy (ATTR-CM). It reveals a 9.9-point treatment difference at month 30 and meaningful gains in alive and well and alive and better outcomes. By integrating survival with patient-reported health status, the authors provide a more meaningful measure of benefit in a progressive, often fatal disease. However, we question whether the overall estimate depends on the chosen imputation strategy
247
9
Residual Peridevice Leak 45 Days After Left Atrial Appendage Occlusion https://jamanetwork.com/journals/jamacardiology/fullarticle/2856899 This cohort study evaluates the association between 45-day peridevice leak severity and long-term thromboembolic outcomes after left atrial appendage occlusion.
249
10
Blood-Based Biomarker Testing for Alzheimer Disease in US Clinical Practice https://jamanetwork.com/journals/jama/fullarticle/2856893 This cohort study examines the rates of blood-based biomarker testing for Alzheimer disease in US clinical practice, exploring patient characteristics, ordering clinician specialty, and diagnostic and treatment events.
342
11
Conversations With Vaccine-Hesitant Patients https://jamanetwork.com/journals/jama/fullarticle/2856894 This JAMA Insights discusses different ways for clinicians to approach conversations with vaccine-hesitant patients, including understanding patients’ attitude roots and empathetic refutational interviewing.
341
12
Digital Delivery of APOE and P-tau217 Results https://jamanetwork.com/journals/jamaneurology/fullarticle/2856813 This randomized clinical trial evaluates noninferiority of delivering apolipoprotein E and plasma phosphorylated tau 217 results digitally vs through a clinician.
438
13
Toward a Healthier Future Through Obesity Prevention and Care https://jamanetwork.com/journals/jama/fullarticle/2856764 This Special Communication discusses the nature of the obesity epidemic; strengths and weaknesses of current approaches to it, including GLP-1 drugs; and roles for different stakeholders.
543
14
Call for Papers on the Future of Obesity https://jamanetwork.com/journals/jama/fullarticle/2856969 With 1 in 7 people (1.1 billion) worldwide affected by obesity, the possibility of widespread, effective medical treatment for this chronic condition has catalyzed a field previously beset by a sense of fatalism. The glucagon-like peptide-1 (GLP-1) and multiple receptor agonist peptide and nonpeptide therapies have yielded weight loss outcomes exceeding what their most ardent proponents could have imagined. Yet the availability of these novel therapeutics is limited by access and adverse effects. Perhaps even more important, their integration into an overall strategy addressing the complex biological, behavioral, socioeconomic, and environmental factors underpinning overweight and obesity is nascent at best.
524
15
Blood Conservation and Choice in Surgical Transfusion https://jamanetwork.com/journals/jama/fullarticle/2856799 This Viewpoint discusses blood conservation and surgical transfusion, including patient blood management and bloodless medicine and surgery, among patients who refuse blood.
570
16
Alcohol Consumption During Pregnancy in the US—Reply https://jamanetwork.com/journals/jama/fullarticle/2856800 In Reply We thank Dr Fan and colleagues for their thoughtful letter and for engaging with our study, which reported an increasing trend in alcohol consumption during pregnancy in the US over the past 2 decades. As discussed by the authors, our descriptive results indicate that older maternal age and tobacco use were both notable correlates of any alcohol use, raising questions about overlapping exposure patterns and potential synergistic effects. While our study was designed to assess population-level trends and does not address etiologic aims directly, we are encouraged that the findings have raised other substantive research questions that could have important implications for prevention and practice.
535
17
Alcohol Consumption During Pregnancy in the US https://jamanetwork.com/journals/jama/fullarticle/2856801 To the Editor The Research Letter by Dr Bruzelius and colleagues documents increased prevalence of alcohol use among pregnant women in the US from 2011 to 2024, particularly among those with older maternal age (35-49 years; 18.2%) and tobacco use (26.3%). Among pregnant women reporting any alcohol use, 68.1% of those who used tobacco also reported binge or heavy drinking, compared with 31.3% of people who did not use tobacco, suggesting a particularly high-risk subgroup that warrants further investigation.
437
18
GLP-1 Utilization After Withdrawal of Medicaid Coverage for Weight Loss https://jamanetwork.com/journals/jama/fullarticle/2856802 This cross-sectional study uses data from Medicaid State Drug Utilization Data to examine associations of coverage withdrawal with Medicaid beneficiaries’ utilization of weight loss–approved glucagon-like peptide-1s.
351
19
Absolute Risk of Progression to Cognitive Impairment Based on Plasma p-Tau217, Age, Sex, and APOE ε4 https://jamanetwork.com/journals/jamaneurology/fullarticle/2856722 This cohort study examines data from the Mayo Clinic Study of Aging and Alzheimer’s Disease Neuroimaging Initiative to determine the 5- and 10-year absolute risks of mild cognitive impairment and dementia among individuals who are biomarker positive and cognitively unimpaired.
351
20
Agent Orange Exposure and Parkinson Disease Among US Veterans https://jamanetwork.com/journals/jamaneurology/fullarticle/2856723 This cohort study investigates the association between Agent Orange and risk of incident Parkinson disease diagnosis among US veterans.
306